Status:
COMPLETED
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Breast Cancer
Eligibility:
FEMALE
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of continued administration of paclitaxel given weekly in subjects considered to need to continue treatment after completion of the pre...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participated in the preceding phase II clinical study
Exclusion
Key Trial Info
Start Date :
June 30 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2008
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00971945
Start Date
June 30 2005
End Date
March 31 2008
Last Update
May 25 2021
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Nagoya, Aichi-ken, Japan, 464-8681
2
Local Institution
Hiroshima, Hiroshima, Japan, 731-0293
3
Local Institution
Kagoshima, Kagoshima-ken, Japan, 892-0833
4
Local Institution
Toshima-ku, Tokyo, Japan, 170-8455